Dutton Associates Announces Investment Opinion: Arbios Systems Strong Speculative Buy Rating Maintained By Dutton Associates.EL DORADO HILLS, Calif. -- Dutton Associates updates coverage of Arbios Systems (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ABOS ABOS American Board of Orthopaedic Surgery ) maintaining a Strong Speculative Buy rating and a 18 month $10 price target. The 10-page report by Dutton senior analyst Bal Bagwat MD, CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. (R) is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex, and other leading financial portals. On April 22, 2005, Arbios received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval for a clinical trial to test SEPET SEPET System Electrical Performance and Evaluation Test (TM)'s safety and tolerability in patients with acute exacerbation of chronic liver failure liver failure Clinical medicine Liver insufficiency that results in death, requires a liver transplant, or is characterized by recovery after encephalopathy, or while awaiting a transplant; also defined as a condition with ≥ 3 of following: albumin < 3. , which is the largest subset of patients admitted to the hospital in acute liver failure Acute liver failure is the appearance of severe complications rapidly after the first signs of liver disease (such as jaundice), and indicates that the liver has sustained severe damage (loss of function of 80-90% of liver cells). . It is estimated that over 360,000 patients are admitted to hospitals in the United States Lists of hospitals for each U.S. state:
ICU abbr. intensive care unit ICU see intensive care unit. ICU and stabilization of the acutely ill patient until the patient's liver can regenerate, precluding the need for expensive liver transplantation surgery and requisite follow-up care. It has a world-renowned scientific team of hepatologists and bioartificial liver innovators. It is possible SEPET(TM) commercialization may be approved by the FDA on or before 2007. The probability of success is predicated on the management of Arbios Systems obtaining FDA approval to commercialize SEPET(TM) and securing a strategic large-cap partnership agreement with favorable royalty terms. Arbios will require significant additional capital during the next 12 to 18 months for the SEPET(TM) and subsequent bioartificial liver clinical trials. About Dutton Associates Dutton Associates is one of the largest independent investment research firms in the U.S. Its 27 senior analysts are primarily CFAs, and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 95 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors. The cost of enrollment in our one-year continuing research program is US $33,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $33,000 from the Company for 4 Research Reports with coverage commencing on 1/24/2005. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion